Silexion Therapeutics Corp (SLXN)
Silexion Therapeutics Corp is a biotechnology company focused on developing RNA interference (RNAi)-based cancer therapies and related delivery systems for malignant solid tumors. Its work is centered on the proprietary LODER delivery platform, which is being applied to several oncology programs. The company’s pipeline includes SiG12D-LODER, which has completed pre-clinical work and an open-label Phase I study in pancreatic cancer, as well as Prostate-LODER and GBM-LODER, both of which remain in pre-clinical development for prostate cancer and glioblastoma multiforme, respectively. Silexion Therapeutics also has a collaboration with Evonik Corporation aimed at developing an advanced siRNA formulation to support cancer treatment. Founded in 2008, the company is headquartered in Jerusalem, Israel.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SLXN
|
$0.50
|
27.3% Upside
|
Undervalued
|
$5 1,175.5% Upside
|
Not available
|
Bargain
|
Weak
|
0.0%
|
November 18, 2026
|
68.7x
|
2.181 M
|
2.204 M
|
31.8%
|
99.9%
|
-66.6
|
89.1%
|
